<DOC>
	<DOCNO>NCT02052154</DOCNO>
	<brief_summary>Evaluate immunogenicity innovative pneumococcal vaccination strategy splenectomized adult comprise 1 dose Prevenar13® conjugate vaccine ( PCV ) M0 follow 1 dose Pneumo23® Pneumovax® polysaccharide vaccine ( PPSV ) M6 . Duration follow-up 36 month . The main endpoint proportion subject responsive 9 13 serotypes common PCV PPSV vaccine , select frequency invasive infection adult France potentially reduce susceptibility penicillin ( serotypes 1 , 3 , 6A , 7F , 9V , 14 , 19A , 19F , 23F ) .</brief_summary>
	<brief_title>Multicenter Pilot Study Evaluating Immunogenicity Innovative Pneumococcal Vaccination Strategy Splenectomized Adults</brief_title>
	<detailed_description>The splenectomized patient susceptible infection lack specific response polysaccharide antigens compose capsule certain bacteria . These severe infection know Overwhelming Post Splenectomy Infections , OPSI ; characterize rapid onset prodrome carry high mortality rate . The annual incidence OPSI estimate 0.23-0.42 % lifetime risk 5 % . The role pneumococcus particular clearly establish infection . The effective strategy minimize risk pneumococcal infection pneumococcal vaccination . Currently two type vaccine available France : polysaccharide conjugate , induce production anti-capsular IgG neutralize opsonic activity . Since one consequence asplenia absence IgM production elicit polysaccharide challenge , due absence splenic B cell , difficult imagine patient would mount satisfactory immune response PPSV vaccination . And fact , several study describe occurrence pneumococcal OPSI patient correctly vaccinate . The study hypothesis vaccination strategy combine PCV vaccine follow PPSV vaccine induce good immune response splenectomized patient , good tolerability . All available data suggest optimum schedule consist primovaccination one dose PCV follow two month later one dose PPSV , order achieve T-dependent memory response 13 serotypes common two vaccine . The propose endpoint therefore evaluate immunogenicity safety vaccination strategy comprise prim one dose Prevenar13® PCV vaccine ( serotypes 4 , 6B , 9V , 14 , 18C , 19F , 23F , + 1 , 3 , 5 , 6A , 7F , 19A ) induce T cell memory response , follow classical administration one dose Pneumo23® Pneumovax® vaccine ( serotypes 1 , 2 , 3 , 4 , 5 , 6B , 7F , 8 , 9N , 9V , 10A , 11A , 12F , 14 , 15B , 17F , 18C , 19F , 19A , 20 , 22F , 23F , 33F ) . Secondary endpoint evaluate safety strategy term post-immunization local systemic side effect , frequency invasive pneumococcal infection , predictor immunogenicity , persistence immunogenicity 30 month post-immunization .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>• Age ≥ 18 year ≤ 75 year Splenectomized since least 2 week , HowellJolly body blood smear ultrasonographic confirmation No immunosppressived condition : mainly trauma , idiopathic thrombocytopathic purpura autoimmune hemolytic anemia , active treatment Available 37 month followup start screen visit Contraception investigator judge effective first 2 month trial , negative pregnancy test Women plan become pregnant 6 month follow inclusion ( M0 ) Signed informed consent Pregnancy plan pregnancy 2 month follow inclusion ( M0 ) Pathology condition modify immune response ( exclude splenectomy ) : HIV infection , immunosuppressive therapy ongoing 6 month inclusion ( M0 ) , include corticosteroid &gt; 10 mg daily , topic inhale dermic corticoid treatment allow , hematopoietic stem cell allo / autograft , primary immune deficiency , nephrotic syndrome , sickle cell disease , evolutive neoplasia History anaphylactic reaction follow vaccination Known allergy ingredient vaccine : aluminium phosphate , phenol , Corynebacterium diphtheriae CRM197 protein Previous vaccination 7valent 13valent pneumococcal conjugate vaccine ( 5 last year ) Previous vaccination pneumococcal polysaccharidic vaccine 3 year inclusion ( M0 ) Other vaccination month inclusion ( M0 ) Polyvalent immunoglobulin infusion 3 month inclusion ( M0 ) plan duration study Anticoagulant treatment current stop less 7 day inclusion ( M0 ) ; clot disorder contraindicate intramuscular injection Participation vaccine study 28 day inclusion till end study Not cover national health insurance ( beneficiary assignee )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pneumococcal infection</keyword>
	<keyword>Splenectomized</keyword>
	<keyword>vaccination</keyword>
</DOC>